News Sentiment

BCAX sentiment intelligence

Bicara Therapeutics Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.76 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-4.0% over one week, +19.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Bicara Therapeutics (BCAX) Corporate presentation Summary

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend active 19.5% over four weeks
Fair value 65.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 45
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 8
Investing.com 5
TradingView 5
Quartr 4
Investing.com Nigeria 3
Motley Fool 3
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 20
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Quartr Direct company coverage

Bicara Therapeutics (BCAX) Corporate presentation Summary

Bicara Therapeutics (BCAX) presented a corporate summary focusing on its lead candidate, ficerafusp alfa (FICERA), a bifunctional antibody targeting EGFR and TGF-β for HPV-negative head and neck squamous cell carcinoma (HNSCC). The company highlighted FICERA's potential for block

Tone
Positive 82/100
Event
Market update
Published
20 Jul 2026 20:09
Source
Quartr
Quartr Direct company coverage

Bicara Therapeutics (BCAX) Study update Summary

Bicara Therapeutics (BCAX) released a study update on May 22, 2026, detailing the efficacy and safety of Ficera (ficerafusp alfa) plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The phase 1/1b expansion cohorts sho

Tone
Positive 93/100
Event
Market update
Published
20 Jul 2026 11:09
Source
Quartr
Quartr Direct company coverage

Bicara Therapeutics (BCAX) Proxy filing Summary

Bicara Therapeutics (BCAX) has scheduled its Annual Meeting for June 9, 2026, with voting concluding on June 8, 2026. Key agenda items include the election of Christopher Bowden, M.D., and Carolyn Ng, Ph.D., as Class II directors, and the ratification of KPMG LLP as the independe

Tone
Positive 63/100
Event
Market update
Published
19 Jul 2026 16:10
Source
Quartr
Quartr Direct company coverage

Bicara Therapeutics (BCAX) Q1 2026 earnings summary

Bicara Therapeutics (BCAX) reported its Q1 2026 earnings, highlighting progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, with enrollment expected by year-end 2026 and interim analysis in mid-2027. The company's cash reserves increased to $539.8M following a $161.8M

Tone
Positive 68/100
Event
Earnings
Published
18 Jul 2026 21:09
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com

This article reports on a Form 4 filing for Bicara Therapeutics Inc. on July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article provides only this headline information and includes no further details abou

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 02:11
Source
Investing.com Nigeria
Investing.com Direct company coverage

Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock

Bicara Therapeutics CEO Claire Mazumdar sold approximately $284,198 worth of common stock on July 10, 2026, through a pre-arranged trading plan. Concurrently, she acquired 10,000 shares by exercising stock options for $37,898. The transactions follow a 177% surge in Bicara's stoc

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 21:42
Source
Investing.com
Stock Titan Direct company coverage

Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan

Bicara Therapeutics Inc. CEO Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share and subsequently sold all 10,000 shares in open-market transactions on July 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan ado

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:42
Source
Stock Titan
Sahm Direct company coverage

Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX)

Bicara Therapeutics recently released encouraging extended follow-up data for its ficerafusp alfa with pembrolizumab in HPV-negative head and neck squamous cell carcinoma. This positive clinical news follows a sale of company stock by CFO Hyep Ivan, creating mixed signals for inv

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 14:10
Source
Sahm
TradingView Direct company coverage

Enterprise value to revenue forward of Bicara Therapeutics Inc. – NASDAQ:BCAX

The article provides the enterprise value to revenue forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It specifies that the market is closed and no trades were made, listing this financial metric within the company's detailed profile on TradingView.

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 14:09
Source
TradingView
Stock Titan Direct company coverage

Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options for 18,750 shares and subsequently sold 28,750 shares of common stock between July 8-9, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices ranging f

Tone
Negative 40/100
Event
Market update
Published
11 Jul 2026 13:11
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Bicara Therapeutics Inc. Insider Trading Activity

Bicara Therapeutics Inc.'s Chief Financial Officer, Ivan Hyep, reported exercising stock options for 12,500 shares and selling 28,000 common shares on July 8, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved selling shares at weighted ave

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 01:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com

This article announces the filing of Form 144 for Bicara Therapeutics Inc. on July 10. Such filings indicate an insider's intent to sell restricted or controlled securities, making this relevant for investors watching company insider activity. The article also mentions the stock

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:28
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com

This article reports on the filing of Form 4 for Bicara Therapeutics Inc. on July 10th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in the company's stock. The article mentions the compa

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:20
Source
Investing.com South Africa
TradingView Direct company coverage

Enterprise value to EBIT forward of Bicara Therapeutics Inc. – NASDAQ:BCAX

This article focuses on the enterprise value to EBIT forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It presents a specific financial metric for the company, indicating data relevant to investors and financial analysts. The rest of the content includes standard navigation an

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:10
Source
TradingView
Investing.com Direct company coverage

Bicara therapeutics president & COO sells $833k in stock

Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, sold approximately $833,129 worth of stock on July 8 and 9, 2026, under a pre-arranged trading plan. This followed an exercise of stock options worth $71,058. The sales occurred while the stock was near its 52-week high

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Investing.com
Investing.com Direct company coverage

Bicara Therapeutics CFO Hyep Ivan sells $807k in stock

Bicara Therapeutics CFO Hyep Ivan sold approximately $807,671 worth of common stock on July 8, 2026, with shares trading near their 52-week high after a significant 199% return. Concurrently, Mr. Hyep acquired 12,500 shares through stock option exercise as part of a Rule 10b5-1 t

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Investing.com
Investing.com Canada Direct company coverage

Bicara therapeutics president & COO sells $833k in stock By Investing.com

Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ:BCAX), sold approximately $833,129 worth of stock following the exercise of stock options. These transactions, executed under a Rule 10b5-1 trading plan, occurred as the stock traded near its 52-week high, despi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:10
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing

An insider at Bicara Therapeutics (NASDAQ: BCAX) recently sold shares amounting to $833,129, as disclosed in a filing with the SEC. The sale was published on July 10, 2026, at 04:20 pm EDT. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bi

Tone
Negative 34/100
Event
Market update
Published
10 Jul 2026 16:20
Source
www.marketscreener.com
TradingView Direct company coverage

Price to book forward of Bicara Therapeutics Inc. – NASDAQ:BCAX

This article provides financial information for Bicara Therapeutics Inc. (NASDAQ: BCAX), specifically focusing on its price-to-book forward ratio. It's presented within the context of TradingView's financial data platform, indicating key financial metrics for the company.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 09:11
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com

Investing.com reported on a Form 144 filing by Bicara Therapeutics Inc. for July 8th, indicating an insider transaction or an intent to sell restricted securities. The article, primarily a brief announcement, also includes current stock market data and a disclaimer about trading

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:11
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX)

BCAX has filed a Form 144 notice disclosing the planned sale of 28,750 shares. This includes 10,000 shares from an option exercise on May 12, 2024, and 18,750 shares from another exercise on July 8, 2026. The filing also reports two recent sales by Ryan Cohlhepp: 12,500 shares fo

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted

An affiliate of Bicara Therapeutics Inc. (BCAX) has filed a Rule 144 notice, indicating proposed sales of 28,000 shares valued at $847,000.00. The filing also detailed two past sales of 9,200 shares each on April 21, 2026, and May 21, 2026, with proceeds of $211,613.80 and $187,8

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
Stock Titan